iBio, Inc. (IBIO) Announced iBioLaunch Platform’s Successful Production of Hookworm Vaccine Antigen
iBio, Inc., a biotechnology company that engages in the development of vaccines and therapeutic proteins, recently announced that its iBioLaunch™ Platform has successfully produced the hookworm-derived molecule, known as NaAPR1M-75. The Antigen will be evaluated as a potential vaccine candidate to be used for the human hookworm disease. The success has been derived from the collaboration between iBio’s research partner, the Fraunhofer Center for Molecular Biotechnology (FCMB) and the Sabin Vaccine Institute. Production for the initial quantities of partially purified NaAPR1M-74 was completed last week at FCMB’s pilot manufacturing facility that utilizes the iBioLaunch Technology. The product was then transferred…